About this trial
Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.
Eligibility criteria
Qualifiers
patients with advanced lung tumor or other solid tumor where biopsy is obtainable
Life expectancy >12 weeks
Child-Pugh-Turcotte score <7
Adequate heart,lung,liver,kidney function
Disqualifiers
Had accepted gene therapy before;
Tumor size more than 25cm;
Severe virus infection such as HBV, HCV, HIV, et al
Known HIV positivity
Trial design
Treatments tested in this trial
- TCR-T cells
Treatment groups
Sponsors and collaborators
Second Affiliated Hospital of Guangzhou Medical University
Lead sponsor
Tcell Immune (Guangzhou) Science and Technology Ltd.
Collaborator